The Global Cannabis based epilepsy drugs Market Size is set to register impressive CAGR of 46% during the forecast period to create high incremental opportunity for industry players. Expected FDA approval of first ever marijuana based drug – Epidiolex will revolutionize the healthcare industry. Many new players might emerge in the market citing high lucrative revenue opportunity.

Download Cannabis based Epilepsy Drugs Market Report Sample:  Get Sample Report

Over 50 million people are currently living with epilepsy with nearly 2.5 million population are diagnosed each year. This is quite prominent in developing regions of Asia Pacific and Latin America–requiring medical care to survive. Need for better treatment modalities along with higher ate revenue opportunity for players engaged in offering treatment drugs for epilepsy.

Epilepsy is a chronic mental disorders that primarily affects middle aged and geriatrics population globally. Social stigma along with no specific treatment drug availability has affected the target population. Once approved, the engaged company will be able to scale up the revenue and become the market leader with brand settlement.

Global Cannabis based Epilepsy Drugs Market Analysis, By Therapeutic Application

The drug will be able to cure various type of epilepsy including Dravet Syndrome (DS) and Lenox Gastaut Syndrome (LGS). These diseases are diagnosed in childhood – that often leads to developmental issues. There are wide range of antiepileptic drugs available in the market – however, none of them is primarily focused on DS and LGS. As such, market approval of Epidiolex will be the footstep towards new mode of therapeutic options. According to FDA, Epidiolex is able to reduce the seizures in DS and LGS by 40%.

Global Cannabis based Epilepsy Drugs Market Analysis, By Distribution Channel

Hospitals, pharmacies, mental hospitals, drug stores and NGO’s will be the key distribution channel. Initially, NGOs and Mental hospitals will account for majority of the market share.

Global Cannabis based Epilepsy Drugs Market Size and Forecast Analysis: Europe to dominate global sales

Globally, North America and Western Europe are expected to dominate the global sales owing to better healthcare facilities, good distribution network, higher prevalence of patients with epilepsy along with favorable regulatory compliances. Government support could further scale up the business in these regions.

Global Cannabis based Epilepsy Drugs Market Size and Forecast: Competition Landscape

GW Pharmaceuticals is the company expected to receive FDA approval for cannabinoids treatment for epilepsy. Once marketed, company will be able to expand its market presence worldwide. There might few more players emerge in the market citing profitability margin and large addressable market.

Cannabis based Epilepsy Drugs Market Industry Segmentation

By Therapeutic Application:

• Dravet Syndrome
• Lenox Gastaut Syndrome

By Distribution Network:

• Hospitals
• Pharmacies
• Drug Stores
• Mental Hospitals
• NGOs

What Will You Discover in the Report?

• An in-depth analysis of the Cannabis based Epilepsy Drugs market across regions – North America, Latin America, Western Europe, Central and Eastern Europe, Asia Pacific, Middle East, and Africa.
• How the Cannabis based Epilepsy Drugs market sales is expected to grow throughout the forecast period.
• How geopolitical policies and technological changes will affect the Cannabis based Epilepsy Drugs market in near future
• Where the stakeholders should invest to generate higher profit margins
• How consumers (end-users) will reflect to the Cannabis based Epilepsy Drugs industry during the forecast period
• Who are the Cannabis based Epilepsy Drugs industry leaders and what are the key initiatives taken by them for long term growth

Analyst access with Bekryl Market Analysts

Purchasing of Cannabis based Epilepsy Drugs market research report will give clients access to 120 minutes telephonic access with a research analyst. The duration for access to analysts will be based on the report subscription editions.